Geneva, Switzerland 2 June 2016 - Addex Therapeutics (SIX: ADXN), announced today that its Annual General Meeting will take place on Thursday, 23 June 2016, at 11:00am at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30am).
Agenda
1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 2015.
2. Consultative vote on the Compensation Report for the business year 2015.
3. Appropriation of the results.
4. Discharge of the members of the Board of Directors and of the Executive Management.
5. Re-elections of members of the Board of Directors and of the Chairman of the Board of Directors
5.1. Re-election of Vincent Lawton as member and Chairman of the Board of Directors;
5.2. Re-election of Raymond Hill as member of the Board of Director; and
5.3. Re-election of Timothy Dyer as member of the Board of Director.
6. Re-elections of Vincent Lawton and Raymond Hill as the members of the Compensation Committee
7. Re-election of PricewaterhouseCoopers SA, Geneva as Auditors.
8. Re-election of Robert P. Briner, attorney-at-law, Briner & Brunisholz, Cours des Bastions 5, CH-1205 Geneva as the Independent Voting Rights Representative.
9. Amendments to the Articles of Association
9.1. Extension and increase of the authorized share capital (article 3b of the Articles of Association);
9.2. Increase of the conditional share capital (article 3c of the Articles of Association); and
10. Approval of the Compensation of the members of the Board of Directors and of the Executive Management
10.1. Approval of Compensation of the members of the Board of Directors; and
10.2. Approval of Compensation of the members of the Executive Management.
11. Miscellaneous.
The detailed Annual General Meeting invitation can be found on the Addex Therapeutics website at www.addextherapeutics.com.
About Addex Therapeutics
Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a phase IIa POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter phase III for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start phase I and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM for neurodegenerative diseases, mGluR7NAM for psychosomatic disorders and TrkBPAM for neurodegenerative disorders which are being advanced in collaboration with the Universities of Lausanne and Geneva under the Swiss CTI grant program; and mGluR3PAM which is being advanced in collaboration with Pierre Fabre Pharmaceuticals. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.
Agenda
1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 2015.
2. Consultative vote on the Compensation Report for the business year 2015.
3. Appropriation of the results.
4. Discharge of the members of the Board of Directors and of the Executive Management.
5. Re-elections of members of the Board of Directors and of the Chairman of the Board of Directors
5.1. Re-election of Vincent Lawton as member and Chairman of the Board of Directors;
5.2. Re-election of Raymond Hill as member of the Board of Director; and
5.3. Re-election of Timothy Dyer as member of the Board of Director.
6. Re-elections of Vincent Lawton and Raymond Hill as the members of the Compensation Committee
7. Re-election of PricewaterhouseCoopers SA, Geneva as Auditors.
8. Re-election of Robert P. Briner, attorney-at-law, Briner & Brunisholz, Cours des Bastions 5, CH-1205 Geneva as the Independent Voting Rights Representative.
9. Amendments to the Articles of Association
9.1. Extension and increase of the authorized share capital (article 3b of the Articles of Association);
9.2. Increase of the conditional share capital (article 3c of the Articles of Association); and
10. Approval of the Compensation of the members of the Board of Directors and of the Executive Management
10.1. Approval of Compensation of the members of the Board of Directors; and
10.2. Approval of Compensation of the members of the Executive Management.
11. Miscellaneous.
The detailed Annual General Meeting invitation can be found on the Addex Therapeutics website at www.addextherapeutics.com.
About Addex Therapeutics
Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a phase IIa POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter phase III for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start phase I and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM for neurodegenerative diseases, mGluR7NAM for psychosomatic disorders and TrkBPAM for neurodegenerative disorders which are being advanced in collaboration with the Universities of Lausanne and Geneva under the Swiss CTI grant program; and mGluR3PAM which is being advanced in collaboration with Pierre Fabre Pharmaceuticals. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.
